Haemophilia

© John Wiley & Sons Ltd

Cover image for Vol. 10 Issue s4

October 2004

Volume 10, Issue Supplement s4

Pages 1–220

  1. State of the Art XXVIth International Congress of The World Federation of Hemophilia The Management of Haemophilia

    1. Top of page
    2. State of the Art XXVIth International Congress of The World Federation of Hemophilia The Management of Haemophilia
    3. Treatment Products
    4. Prophylaxis
    5. Laboratory Aspects of Haemophilia Therapy
    6. Genetic Aspects of Haemophilia
    7. Inhibitors
    8. Musculoskeletal Aspects of Haemophilia
    9. von Willebrand Disease
    10. Other Bleeding Disorders
    11. HCV and HIV
    12. Late-Breaking Article
    1. WFH: back to the future (pages 1–8)

      B. O'Mahony

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00981.x

    2. Comprehensive care for haemophilia around the world (pages 9–13)

      B. L. Evatt, C. Black, A. Batorova, A. Street and A. Srivastava

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.01010.x

    3. Haemophilia in the developing world: successes, frustrations and opportunities (pages 14–19)

      M. Tezanos Pinto and Z. Ortiz

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00986.x

    4. Evidence-based treatment of haemophilia (pages 20–24)

      P. H. B. Bolton-Maggs, K. Stobart and R. L. Smyth

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00994.x

    5. Models for psychosocial services in the developed and developing world (pages 25–29)

      M. Spilsbury

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.01002.x

    6. Disease-specific quality-of-life measurement tools for haemophilia patients (pages 30–34)

      E. Remor, N. L. Young, S. Von Mackensen and E. G. Lopatina

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.01004.x

    7. Minimizing factor requirements for surgery without increased risk (pages 35–40)

      S. Schulman, J. Loogna and R. Wallensten

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1745-6584.2005.0048.x

    8. The impact of information technology on haemophilia care (pages 41–46)

      R. I. Baker, L. Laurenson, M. Winter and A. M. Pritchard

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00995.x

  2. Treatment Products

    1. Top of page
    2. State of the Art XXVIth International Congress of The World Federation of Hemophilia The Management of Haemophilia
    3. Treatment Products
    4. Prophylaxis
    5. Laboratory Aspects of Haemophilia Therapy
    6. Genetic Aspects of Haemophilia
    7. Inhibitors
    8. Musculoskeletal Aspects of Haemophilia
    9. von Willebrand Disease
    10. Other Bleeding Disorders
    11. HCV and HIV
    12. Late-Breaking Article
    1. Emerging and receding risks of therapeutic regimens for haemophilia (pages 47–54)

      A. Farrugia, C. S. Manno and B. L. Evatt

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.01006.x

    2. New high-technology products for the treatment of haemophilia (pages 55–63)

      S. W. Pipe, J-M. Saint-Remy and C. E. Walsh

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00996.x

    3. Variant Creutzfeldt–Jakob disease: risk of transmission by blood and blood products (pages 64–69)

      J. W. Ironside and M. W. Head

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00982.x

    4. Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide (pages 70–76)

      K. E. Van Cott, P. E. Monahan, T. C. Nichols and W. H. Velander

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00983.x

    5. Product delivery in the developing world: options, opportunities and threats (pages 77–82)

      A. Farrugia

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.01007.x

    6. Regulatory challenges to global harmonization and expanded access to concentrates: how will regulators balance the increasing cost of new safety requirements with the desire to increase the availability of affordable product? (pages 83–87)

      A. Farrugia

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.01040.x

  3. Prophylaxis

    1. Top of page
    2. State of the Art XXVIth International Congress of The World Federation of Hemophilia The Management of Haemophilia
    3. Treatment Products
    4. Prophylaxis
    5. Laboratory Aspects of Haemophilia Therapy
    6. Genetic Aspects of Haemophilia
    7. Inhibitors
    8. Musculoskeletal Aspects of Haemophilia
    9. von Willebrand Disease
    10. Other Bleeding Disorders
    11. HCV and HIV
    12. Late-Breaking Article
    1. Physical therapy and imaging outcome measures in a haemophilia population treated with factor prophylaxis: current status and future directions (pages 88–93)

      M. J. Manco-Johnson, H. Pettersson, P. Petrini, P. S. Babyn, B-M. Bergstrom, C.-S. Bradley, A. S. Doria, B. M. Feldman, S. Funk, P. Hilliard, R. Kilcoyne, B. Lundin, R. Nuss, G. Rivard, M. A. G. C. Schoenmakers, M. Van den berg, J. Wiedel, N. Zourikian and V. S. Blanchette

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00978.x

    2. Towards the goal of prophylaxis: experience and treatment strategies from Sweden, France and Hungary (pages 94–96)

      P. Petrini, H. Chambost and L. Nemes

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00987.x

    3. Optimizing factor prophylaxis for the haemophilia population: where do we stand? (pages 97–104)

      V. S. Blanchette, M. Manco-Johnson, E. Santagostino and R. Ljung

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00998.x

  4. Laboratory Aspects of Haemophilia Therapy

    1. Top of page
    2. State of the Art XXVIth International Congress of The World Federation of Hemophilia The Management of Haemophilia
    3. Treatment Products
    4. Prophylaxis
    5. Laboratory Aspects of Haemophilia Therapy
    6. Genetic Aspects of Haemophilia
    7. Inhibitors
    8. Musculoskeletal Aspects of Haemophilia
    9. von Willebrand Disease
    10. Other Bleeding Disorders
    11. HCV and HIV
    12. Late-Breaking Article
    1. Essential issues of laboratory investigation for patients with haemophilia and bleeding disorders (pages 105–108)

      A. Chuansumrit, A. McCraw and E. F. Preston

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00988.x

    2. Monitoring haemophilia severity and treatment: new or old laboratory tests? (pages 109–114)

      T. W. Barrowcliffe

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00985.x

  5. Genetic Aspects of Haemophilia

    1. Top of page
    2. State of the Art XXVIth International Congress of The World Federation of Hemophilia The Management of Haemophilia
    3. Treatment Products
    4. Prophylaxis
    5. Laboratory Aspects of Haemophilia Therapy
    6. Genetic Aspects of Haemophilia
    7. Inhibitors
    8. Musculoskeletal Aspects of Haemophilia
    9. von Willebrand Disease
    10. Other Bleeding Disorders
    11. HCV and HIV
    12. Late-Breaking Article
    1. What is a cure and how do we get there? (pages 115–118)

      M. W. Skinner, D. P. Lillicrap, J. McMillan, M. Castro Ozelo and G. F. Pierce

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00999.x

    2. Preclinical and clinical gene therapy for haemophilia (pages 119–125)

      M. K. L. Chuah, D. Collen and T. Vandendriessche

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00984.x

    3. Preimplantation genetic diagnosis: new reproductive options for carriers of haemophilia (pages 126–132)

      S. Lavery

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.01042.x

    4. Molecular basis of haemophilia A (pages 133–139)

      J. Oldenburg, N. M. Ananyeva and E. L. Saenko

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.01005.x

  6. Inhibitors

    1. Top of page
    2. State of the Art XXVIth International Congress of The World Federation of Hemophilia The Management of Haemophilia
    3. Treatment Products
    4. Prophylaxis
    5. Laboratory Aspects of Haemophilia Therapy
    6. Genetic Aspects of Haemophilia
    7. Inhibitors
    8. Musculoskeletal Aspects of Haemophilia
    9. von Willebrand Disease
    10. Other Bleeding Disorders
    11. HCV and HIV
    12. Late-Breaking Article
    1. Inhibitors in haemophilia: clinical aspects (pages 140–145)

      D. Dimichele, G. Rivard, C. Hay and S. Antunes

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00993.x

    2. Inhibitors in haemophilia: pathophysiology (pages 146–151)

      J-M. R. Saint-Remy, S. Lacroix-Desmazes and J. Oldenburg

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.01009.x

  7. Musculoskeletal Aspects of Haemophilia

    1. Top of page
    2. State of the Art XXVIth International Congress of The World Federation of Hemophilia The Management of Haemophilia
    3. Treatment Products
    4. Prophylaxis
    5. Laboratory Aspects of Haemophilia Therapy
    6. Genetic Aspects of Haemophilia
    7. Inhibitors
    8. Musculoskeletal Aspects of Haemophilia
    9. von Willebrand Disease
    10. Other Bleeding Disorders
    11. HCV and HIV
    12. Late-Breaking Article
    1. The target joint (pages 152–156)

      K. Mulder and A. Llinás

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00976.x

    2. Functional recovery after bleeding episodes in haemophilia (pages 157–160)

      P. De Kleijn, M. Gilbert, G. Roosendaal, P. M. Poonnose, P. M. Narayan and N. Tahir

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00977.x

    3. Risks and benefits of sports and fitness activities for people with haemophilia (pages 161–163)

      K. Mulder, F. Cassis, D. R. A. Seuser, P. Narayan, R. Dalzell and W. Poulsen

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.01000.x

  8. von Willebrand Disease

    1. Top of page
    2. State of the Art XXVIth International Congress of The World Federation of Hemophilia The Management of Haemophilia
    3. Treatment Products
    4. Prophylaxis
    5. Laboratory Aspects of Haemophilia Therapy
    6. Genetic Aspects of Haemophilia
    7. Inhibitors
    8. Musculoskeletal Aspects of Haemophilia
    9. von Willebrand Disease
    10. Other Bleeding Disorders
    11. HCV and HIV
    12. Late-Breaking Article
    1. von Willebrand disease: laboratory aspects of diagnosis and treatment (pages 164–168)

      E. J. Favaloro, D. Lillicrap, M. A. Lazzari, M. Cattaneo, C. Mazurier, A. Woods, S. Meschengieser, A. Blanco, A. C. Kempfer, A. Hubbard and A. Chang

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00979.x

    2. Clinical diagnosis of von Willebrand disease (pages 169–176)

      A. B. Federici

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00991.x

  9. Other Bleeding Disorders

    1. Top of page
    2. State of the Art XXVIth International Congress of The World Federation of Hemophilia The Management of Haemophilia
    3. Treatment Products
    4. Prophylaxis
    5. Laboratory Aspects of Haemophilia Therapy
    6. Genetic Aspects of Haemophilia
    7. Inhibitors
    8. Musculoskeletal Aspects of Haemophilia
    9. von Willebrand Disease
    10. Other Bleeding Disorders
    11. HCV and HIV
    12. Late-Breaking Article
    1. How to evaluate phenotype–genotype relationship in rare coagulation haemorrhagic disorders: examples from FVII deficiency (pages 177–179)

      F. Bernardi, G. Marchetti, A. Dolce and G. Mariani

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00989.x

    2. Clinical picture and management of congenital factor VII deficiency (pages 180–183)

      G. Mariani, A. Dolce, G. Marchetti and F. Bernardi

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00990.x

    3. New observations on factor XI deficiency (pages 184–187)

      O. Salomon and U. Seligsohn

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00992.x

    4. Acquired bleeding disorders: the impact of health problems in the developing world (pages 188–195)

      P. Isarangkura, C. Mahasandana, A. Chuansumrit and P. Angchaisuksiri

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.01008.x

    5. The role of haemophilia treatment centres in providing services to women with bleeding disorders (pages 196–204)

      R. Winikoff, C. Amesse, A. James, C. Lee and D. Pollard

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.01001.x

  10. HCV and HIV

    1. Top of page
    2. State of the Art XXVIth International Congress of The World Federation of Hemophilia The Management of Haemophilia
    3. Treatment Products
    4. Prophylaxis
    5. Laboratory Aspects of Haemophilia Therapy
    6. Genetic Aspects of Haemophilia
    7. Inhibitors
    8. Musculoskeletal Aspects of Haemophilia
    9. von Willebrand Disease
    10. Other Bleeding Disorders
    11. HCV and HIV
    12. Late-Breaking Article
    1. Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia (pages 205–210)

      J. J. Goedert, D. L. Brown, K. Hoots and K. E. Sherman

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00997.x

    2. Hepatitis C in haemophilia: lights and shadows (pages 211–215)

      M. G. Rumi, F. De Filippi, E. Santagostino and M. Colombo

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.00980.x

  11. Late-Breaking Article

    1. Top of page
    2. State of the Art XXVIth International Congress of The World Federation of Hemophilia The Management of Haemophilia
    3. Treatment Products
    4. Prophylaxis
    5. Laboratory Aspects of Haemophilia Therapy
    6. Genetic Aspects of Haemophilia
    7. Inhibitors
    8. Musculoskeletal Aspects of Haemophilia
    9. von Willebrand Disease
    10. Other Bleeding Disorders
    11. HCV and HIV
    12. Late-Breaking Article
    1. Dose and outcome of care in haemophilia – how do we define cost-effectiveness? (pages 216–220)

      K. Fischer, H. M. Van Den Berg, R. Thomas, S. Kumar, P. Poonnoose, A. Viswabandya, V. Mathews, M. L. Kavitha, S. Bhattacharji and A. Srivastava

      Article first published online: 8 OCT 2004 | DOI: 10.1111/j.1365-2516.2004.01047.x

SEARCH

SEARCH BY CITATION